Genetic testing of common and rare variants in dementia patients from a memory clinic

Many types of dementia have high heritability, which creates opportunities for DNA diagnostics. Clinicians sporadically test for causal genetic variants. However, in addition to causal genetic mutations, an increasing number of both common and rare risk factors are being identified, especially for Alzheimer’s disease (AD). Here, we describe and evaluate diagnostic performance of combining genetic risk factors for AD to assist memory clinic clinicians. A retrospective analysis of 998 consecutive patients (mean age 62.1, 40.3% females, 63.3% dementia) was conducted over 2.5 years in a Dutch memory clinic. The patients underwent a complete genetic risk assessment, including whole-exome sequencing and array genotyping. We examined known pathogenic genetic variants for all dementia types and their correlation with clinical diagnoses. We evaluated a combined genetic score (GS) based on all genetic risk factors for AD - namely APOE genotypes, candidate risk rare variants in 11 genes, and a polygenic risk score (PRS) based on 82 common variants. Then, we analyzed the discriminatory characteristics of the GS. Causal pathogenic variants were rare, present in 3.4% of individuals, but genetic testing would have altered the diagnosis in over half of the carriers. Candidate rare risk variants were more common, identified in 31.6% of patients. Both APOE genotypes and the PRS were independently associated with AD, and gene-specific interaction was found between TREM2 and AD-PRS (β = -1.16, p = 0.015). Patients with a high GS were 7 times more likely receive an AD diagnosis compared to those with a low GS (p = 2.5E-07). Overall, this study highlights the potential of integrating genetic risk factors into clinical practice to enhance AD diagnosis, though the improvement in diagnostic accuracy was moderate. The findings underscore the importance of genetic testing in diagnosis while also recognizing its limitations.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2025-10-14
DOI
https://doi.org/10.1186/s13195-025-01854-z
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genetic testing of common and rare variants in dementia patients from a memory clinic

Marc Hulsman, Itziar de Rojas, Wiesje M. van der Flier, Mieke M. van Haelst et al.
Alzheimer s Research & Therapy
Genomics and Rare Diseases
article

Genetic testing of common and rare variants in dementia patients from a memory clinic

Marc Hulsman, Itziar de Rojas, Wiesje M. van der Flier, Mieke M. van Haelst, Henne Holstege, Fred van Ruissen, Marcel Reinders, Philip R. Jansen, Janna I.R. Dijkstra, Jetske van der Schaar, María Victoria Fernández, Yolande A.L. Pijnenburg, Agustín Ruiz, Niccoló Tesi, Sven J. van der Lee, Rosalina M.L. van Spaendonk
article en

Abstract

Many types of dementia have high heritability, which creates opportunities for DNA diagnostics. Clinicians sporadically test for causal genetic variants. However, in addition to causal genetic mutations, an increasing number of both common and rare risk factors are being identified, especially for Alzheimer’s disease (AD). Here, we describe and evaluate diagnostic performance of combining genetic risk factors for AD to assist memory clinic clinicians. A retrospective analysis of 998 consecutive patients (mean age 62.1, 40.3% females, 63.3% dementia) was conducted over 2.5 years in a Dutch memory clinic. The patients underwent a complete genetic risk assessment, including whole-exome sequencing and array genotyping. We examined known pathogenic genetic variants for all dementia types and their correlation with clinical diagnoses. We evaluated a combined genetic score (GS) based on all genetic risk factors for AD - namely APOE genotypes, candidate risk rare variants in 11 genes, and a polygenic risk score (PRS) based on 82 common variants. Then, we analyzed the discriminatory characteristics of the GS. Causal pathogenic variants were rare, present in 3.4% of individuals, but genetic testing would have altered the diagnosis in over half of the carriers. Candidate rare risk variants were more common, identified in 31.6% of patients. Both APOE genotypes and the PRS were independently associated with AD, and gene-specific interaction was found between TREM2 and AD-PRS (β = -1.16, p = 0.015). Patients with a high GS were 7 times more likely receive an AD diagnosis compared to those with a low GS (p = 2.5E-07). Overall, this study highlights the potential of integrating genetic risk factors into clinical practice to enhance AD diagnosis, though the improvement in diagnostic accuracy was moderate. The findings underscore the importance of genetic testing in diagnosis while also recognizing its limitations.

Alzheimer s Research & TherapyVol. 17(1)
The University of Texas at San Antonio Health Science Center (US), University of Luxembourg (LU), Universitat Internacional de Catalunya (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Emma Kinderziekenhuis (NL), Center for Human Genetics (US), Amsterdam Neuroscience (NL), Institute of Human Genetics (PL), GGD Amsterdam (NL), Amsterdam University Medical Centers (NL), Vrije Universiteit Amsterdam (NL), University of Amsterdam (NL), Delft University of Technology (NL)
Health~Holland, ZonMw, Stichting Dioraphte
Openalex Percentile: Top 69%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.